Synthetic mRNA is an attractive vehicle for gene therapies because of its transient nature and improved safety profile over DNA. However, unlike DNA, broadly applicable methods to control expression from mRNA are lacking. Here we describe a platform for small-molecule-based regulation of expression from modified RNA (modRNA) and self-replicating RNA (replicon) delivered to mammalian cells. Specifically, we engineer small-molecule-responsive RNA binding proteins to control expression of proteins from RNA-encoded genetic circuits. Coupled with specific modRNA dosages or engineered elements from a replicon, including a subgenomic promoter library, we demonstrate the capability to externally regulate the timing and level of protein expression. These control mechanisms facilitate the construction of ON, OFF, and two-output switches, with potential therapeutic applications such as inducible cancer immunotherapies. These circuits, along with other synthetic networks that can be developed using these tools, will expand the utility of synthetic mRNA as a therapeutic modality.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $14.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
The authors declare that data supporting the finding of this study are available within the article and its Supplementary Information. Sample analysis of cytometry data can be found in Supplementary Fig. 29. Replicon MoClo assembly plasmids have been submitted to Addgene with the accession numbers 115928, 115929, 115930, 115931, 115932, 115933, 115934, 115935, 115936, 115937, 115938, 115939, 115940, 115941, 115942, 115943, 115944, 115945, 115946, 115947, 115948, 115949, 115950, 115951, 115952, 115953, 115954, 115955, 115956, 115957, 115958, 115959, 115960, 115961, 115962, 115963, 115964, 115965, 115966, and 115967. A more detailed table can be found in Supplementary Fig. 30. Additional data are available from the corresponding authors upon reasonable request.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The authors would like to thank J. Niles, B.J. Belmont, and S. Maddur Ganesan (MIT) for discussions regarding the TetR–aptamer system, A. Ghodasara (MIT) for discussions and technical assistance related to aptamers/aptazymes, and R. Petersen (Designs By Robin) for consultations with figure design and layout. This work was supported by research grants from the Defense Advanced Research Projects Agency (W911NF-11-2-0054: awarded to J.B., D.D., and R.W., supported T.W., J.B.R., X.Z., E.P., J.B., D.D., T.K., and R.W. and W32P4Q-13-1-0011: awarded to R.W., supported X.Z., T.K., and R.W.), the National Science Foundation (NSF#1522074, NSF#1521759: awarded to D.D., supported T.W. and D.D., CCF-1521925: awarded to D.D. and R.W., supported T.W, J.R.B., D.D., and R.W., CNS-1446607: awarded to R.W., supported J.R.B., B.T., and R.W., and MCB-1745645: awarded to R.W., supported J.R.B. and R.W.), the National Institutes of Health (5-R01-CA206218: awarded to R.W., supported J.B.R., E.P., and R.W.), the Ragon Institute of MGH, MIT and Harvard (awarded to R.W., supported A.W. and R.W.), the Special Research Fund from Ghent University (awarded to N.N.S.), and The Research Foundation - Flanders (FWO; G.0235.11N and G.0621.10N: awarded to N.N.S.). This work was also supported by a sponsored research agreement with Crucell Holland B.V. (awarded to R.W., supported: B.D., E.P., and R.W.). We further acknowledge the following support: MIT-Amgen UROP Scholars Program (K.B.), Gabilan Stanford Graduate Fellowship (K.B.), Fannie and John Hertz Foundation Fellowship - Hertz-Draper Fellow (K.B.), Stanford EDGE-STEM Doctoral Fellowship (K.B.), PhD fellowship and international mobility grant from FWO (O.A.), and the Emmanuel van der Schueren fellowship from “Kom op tegen Kanker” (O.A.).